Results 191 to 200 of about 14,491 (226)

Alectinib

Reactions Weekly, 2021
  +5 more sources

A Rare Case of Hemolytic Anemia after Alectinib That Did Not Recur after Switching to Lorlatinib

Case Reports in Oncology
Introduction: We would like to share the case of a 55-year-old male patient with ALK-positive lung cancer with a corpuscular hemolytic anemia following alectinib therapy.
X. Tonnar, Cornelius F. Waller
semanticscholar   +1 more source

A Cost-effectiveness Analysis of Adjuvant Alectinib in Patients With Resectable ALK-positive Non-small Cell Lung Cancer in the United States.

American Journal of Clinical Oncology
OBJECTIVES We evaluated the cost-effectiveness of adjuvant alectinib versus adjuvant platinum-based chemotherapy for patients with resectable (stage IB to IIIA) ALK+ non-small cell lung cancer using a US societal perspective.
Amy L. Cummings, Jesse Sussell, K. Rosettie, Fadoua El Moustaid, S. Ogale, Celina Ngiam, Nick Jovanoski, M. Arnold, Jay M. Lee   +8 more
semanticscholar   +1 more source

MET and NF2 alterations confer primary and early resistance to first‐line alectinib treatment in ALK‐positive non‐small‐cell lung cancer

Molecular Oncology
Although first‐line alectinib has prolonged survival in ALK‐mutated non‐small‐cell lung cancers (NSCLCs), the response to treatment varies among patients, and the primary/early development of alectinib resistance mechanisms is still not fully understood.
Jie Hu, Ning Ding, Xiaobo Xu, Yedan Chen, Yong Zhang, Jingwen Liu, Jie-bai Zhou, Hairong Bao, Donghui Zhang, Yijun Song, Yang Shao, Yuanlin Song   +11 more
semanticscholar   +1 more source

Alectinib in children and adolescents with solid or CNS tumors harboring ALK-fusions: A data update from the iMATRIX alectinib phase I/II open-label, multi-center study.

Journal of Clinical Oncology
10004 Background: Alectinib is a next generation oral inhibitor of ALK-fusion proteins, being investigated in children and adolescents with ALK-fusion bearing tumors at diagnosis or relapse.
François Doz, M. Casanova, Kyung-Nam Koh, K. Nysom, Adela Cañete, H. Kang, M. Karajannis, Darren Hargrave, Nadége Corradini, Yeming Wu, Huanmin Wang, David S. Ziegler, Nicolas Prud'homme, C. Manzitti, Q. Campbell-Hewson, Carolina Sturm, Tao Xu, Dhruvitkumar S. Sutaria, Francis Mussai, Amar Gajjar   +19 more
semanticscholar   +1 more source

Neladalkib (NVL-655), a highly selective anaplastic lymphoma kinase (ALK) inhibitor, compared to alectinib in first-line treatment of patients with ALK-positive advanced non-small cell lung cancer: The phase 3 ALKAZAR study.

Journal of Clinical Oncology
TPS8666 Background: Oncogenic ALK gene fusions are detected in ~5% of advanced non-small cell lung cancer (NSCLC) cases. Among these patients, the incidence of brain metastases at diagnosis is ~40%.
Sanjay Popat, B. Solomon, T. Stinchcombe, Geoffrey Liu, Gilberto Lopes, Melissa L. Johnson, Misako Nagasaka, Ece Cali Daylan, C. Baik, J. D'Olimpio, Tzu-chuan Jane Huang, A. Spira, D. Haggstrom, B. Creelan, Kristina Kehrig, Junwu Shen, Rachel DeLaRosa, V. Zhu, A. Drilon, A. Shaw   +19 more
semanticscholar   +1 more source

Alectinib

Reactions Weekly, 2019
  +7 more sources

Analytical Validation of a Volumetric Absorptive Microsampling Method for Therapeutic Drug Monitoring of the Oral Targeted Anticancer Agents, Abiraterone, Alectinib, Cabozantinib, Imatinib, Olaparib, and Sunitinib, and Metabolites

Therapeutic Drug Monitoring
Supplemental Digital Content is Available in the Text. Background: Volumetric Absorptive Microsampling (VAMS) is a useful tool for therapeutic drug monitoring (TDM) of oral targeted anticancer agents.
M. Meertens, N. de Vries, H. Rosing, N. Steeghs, J. H. Beijnen, A. Huitema   +5 more
semanticscholar   +1 more source

Alectinib

Reactions Weekly, 2022
  +6 more sources

ALK Inhibition With Alectinib for Refractory Metastatic Renal Cell Carcinoma With ALK Rearrangement: A Rare Case Report and Literature Review.

JCO Precision Oncology
ALK-rearranged RCC refractory to several lines of treatment has a durable response when treated with alectinib.
Nikhita Kathuria-Prakash, Lidia P Lopez, Steven S. Raman, Huihui Ye, Jordan Anaokar, Anthony Sisk, A. Pantuck, A. Drakaki   +7 more
semanticscholar   +1 more source